• Gallant, an animal health biotechnology company, recently announced a fulfillment agreement with MWI Animal Health, part of Cencora, to build the first ultra-low temperature cold chain for veterinary medicine and support nationwide distribution of a potential first FDA-approved off-the-shelf veterinary stem cell therapy, pending conditional FDA approval.
• This partnership highlights Cencora’s growing role in specialized logistics for complex biologics, expanding its capabilities in animal health and advanced therapies that require highly controlled distribution.
• We’ll now examine how Cencora’s new ultra-low temperature veterinary cold chain opportunity could influence its investment narrative and long-term positioning.

Find 49 companies with promising cash flow potential yet trading below their fair value.

Cencora Investment Narrative Recap

To own Cencora, you need to believe it can keep growing higher value specialty services even as biosimilars, generics and low margin GLP 1 volumes weigh on fees and margins. The Gallant and MWI ultra low temperature veterinary cold chain agreement fits this thesis by deepening Cencora’s role in complex biologics logistics, but it does not materially change the near term risk that pricing pressure and competition in specialty distribution could limit earnings growth.

The recent US$3.0 billion multi tranche senior notes issuance in February 2026 is the most relevant backdrop for this development, as it adds financial flexibility but also underscores Cencora’s already high leverage. As the company leans further into specialty and ultra cold chain capabilities that support services led growth, investors will likely watch how efficiently this new capital is deployed and whether margins can offset the drag from lower fee products and international softness.

Yet behind the promise of advanced therapies and expanded logistics, investors should be aware that rising leverage and margin pressure could...

Cencora's narrative projects $385.4 billion revenue and $3.3 billion earnings by 2028.

Uncover how Cencora's forecasts yield a $403.79 fair value, a 9% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community span roughly US$404 to US$601 per share, showing how far apart individual views can be. As you weigh those opinions against the risk of margin compression from biosimilars and generics, it is worth exploring how different assumptions about Cencora’s specialty services growth could shape long term outcomes.

Explore 2 other fair value estimates on Cencora - why the stock might be worth just $403.79!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Cencora research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Cencora research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Cencora's overall financial health at a glance.

Searching For A Fresh Perspective?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 22 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution.
• AI is about to change healthcare. These 28 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.